Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany’s Digital Health Fast-Track Scheme: What Manufacturers Need To Know

Executive Summary

Understanding the German reimbursement system is crucial for any medtech firm eyeing the European market, and healthtech innovators in particular may benefit from its fast-track digital health app scheme. But how does the scheme work, and who can apply?

You may also be interested in...



EU Must Adopt Innovative Drugs & AI ‘At Scale’ To Plug Cancer Care Gaps

European countries should establish “implementation budgets” to fund innovative cancer therapies and leverage technologies such as AI in drug R&D to meet the rising demand for cancer care, pharmaceutical industry representatives say.

COCIR Report Maps Digital Health Market Access Routes In 6 European Countries

Diverse national market access pathways for digital health technologies in Europe can make reimbursement tricky to navigate for manufacturers. A report by trade body COCIR maps digital health reimbursement routes in six European countries.

The Serious Business Of Digital Medical Games

There are fewer than a handful of prescription video game digital therapeutics with regulatory clearance, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT146014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel